Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1
The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.59, moving -0.35% from the previous trading session.
Bristol Myers Squibb Co. stock rises Friday, still underperforms market
The stock's fall snapped a two-day winning streak.
MM&M7h
Big Pharma hikes prices of 250 drugs in January
Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.
Companies sold a record $8 trillion of bonds last year amid high demand and lower borrowing costs
Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...
Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
nationthailand22h
Drugmakers raised prices on 250+ medicines in the US starting Jan. 1
Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
This was the stock's second consecutive day of gains.
Drugmakers hike prices to start year as threats to industry loom
Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...
The American Journal of Managed Care1d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
bovnews1d
What’s Behind the 0.89% Gain in Bristol-Myers Squibb Co (BMY) Stock? Find Out Now!
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $56.56 which represents a slight increase of $0.50 or 0.89% from the prior close of $56.06. The stock opened at $56.07 and ...
Jefferies Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report), with a price ...